A prospective randomized controlled trial for clinical intervention for asymptomatic BV (bacterial vaginosis) on persistent HPV (human papilloma virus) infection

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028973

Enrollment

Unknown

Registered

2020-01-10

Start date

2020-01-20

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical HPV infection and BV

Interventions

Experimental group:Metronidazole 0.4 g, bid, po, 7 Days

control group:no treatment

Eligibility

Sex/Gender

Female

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. positive for high-risk HPV (Human Papillomavirus) in the cervix; 2. no previous history of HPV infection; 3. colposcopy to exclude high-level cervical lesions and above; 4. informed consent to participate in the study; 5. aged 18-55 years; 6. Nugent score 4-10.

Exclusion criteria

Exclusion criteria: 1. Coexisting?of vulvar disease; 2. Received surgical or physical therapy for cervical disease; 3. After hysterectomy; 4. Metronidazole allergy; 5. Pathologically confirmed cervical HSIL; 6. The researchers thought they needed to rule out.

Design outcomes

Primary

Measure	Time frame
positive;Nugent Score;	—

Countries

China

Contacts

Public ContactZHANG Dai

Peking University First Hospital

mailzhangdai@sina.com+86 13910552191

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026